TD Asset Management Inc Trims Position in Medpace Holdings, Inc. $MEDP

TD Asset Management Inc cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 59.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,540 shares of the company’s stock after selling 76,607 shares during the period. TD Asset Management Inc’s holdings in Medpace were worth $28,947,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Optiver Holding B.V. purchased a new position in shares of Medpace during the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. Quarry LP purchased a new position in shares of Medpace during the third quarter valued at approximately $35,000. Finally, Core Wealth Advisors LLC purchased a new position in shares of Medpace during the fourth quarter valued at approximately $47,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MEDP shares. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. BMO Capital Markets reduced their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Truist Financial reduced their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Mizuho set a $582.00 target price on Medpace in a research note on Wednesday, February 11th. Finally, Barclays reduced their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $467.08.

Medpace Price Performance

MEDP opened at $454.25 on Monday. The firm has a market cap of $12.97 billion, a PE ratio of 28.55, a P/E/G ratio of 2.30 and a beta of 1.18. The stock has a 50-day moving average price of $456.73 and a 200-day moving average price of $508.39. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.